Access to medication for opioid use disorder supported by telemedicine and healthcare coverage : A web-based survey during the COVID-19 pandemic
© 2023 The Author(s)..
Background and Aims: Medications for opioid use disorder (MOUD) are highly effective in improving treatment outcomes and reducing overdose. Concerns about interrupted access to critical MOUD services led to expansion of telemedicine services during the COVID-19 pandemic in the US. The current study tested the hypothesis that telemedicine usage and healthcare coverage would be significantly associated with access to MOUD in the early phase of the COVID-19 pandemic.
Design: A cross-sectional online survey was administered to a non-probability sample from June 18-July 19, 2020 using the Amazon Mechanical Turk platform.
Setting: Northeastern United States during the early phase of the COVID-19 pandemic. At the time of the survey, federal regulators had waived the longstanding requirement for in-office visits for MOUD prescription receipt and provided guidance on increasing third-party payer reimbursement rates for telehealth visits in order to mitigate barriers to care associated with COVID-19 safety guidelines.
Participants: Individuals 18 years or older residing in Connecticut, Massachusetts, New Jersey, New York, or Rhode Island were eligible to complete the survey. The analytic sample was participants who reported using opioids not as prescribed by a physician in the past seven days.
Measurements: Demographics, telemedicine usage, and healthcare coverage were assessed as explanatory variables. The primary outcome was whether participants reported ability to access MOUD in the past four weeks.
Findings: In this sample of individuals who used illicit opioids in the past week (N = 191), one in two individuals who utilized telehealth or had healthcare coverage were able to access MOUD, whereas only one in five of their respective counterparts who did not have telehealth access or healthcare coverage were able to access these medications.
Conclusions: Telemedicine and healthcare coverage were associated with greater MOUD access early in the COVID-19 pandemic, when barriers to care were high. Such findings speak to the importance of not only extending but also formalizing temporary policy changes instituted during the pandemic to allow MOUD prescribing via telemedicine.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Addictive behaviors reports - 18(2023) vom: 18. Dez., Seite 100515 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Monnig, Mollie A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 pandemic |
|---|
| Anmerkungen: |
Date Revised 22.11.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.abrep.2023.100515 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362287023 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362287023 | ||
| 003 | DE-627 | ||
| 005 | 20231226090925.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.abrep.2023.100515 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM362287023 | ||
| 035 | |a (NLM)37731991 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Monnig, Mollie A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Access to medication for opioid use disorder supported by telemedicine and healthcare coverage |b A web-based survey during the COVID-19 pandemic |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Author(s). | ||
| 520 | |a Background and Aims: Medications for opioid use disorder (MOUD) are highly effective in improving treatment outcomes and reducing overdose. Concerns about interrupted access to critical MOUD services led to expansion of telemedicine services during the COVID-19 pandemic in the US. The current study tested the hypothesis that telemedicine usage and healthcare coverage would be significantly associated with access to MOUD in the early phase of the COVID-19 pandemic | ||
| 520 | |a Design: A cross-sectional online survey was administered to a non-probability sample from June 18-July 19, 2020 using the Amazon Mechanical Turk platform | ||
| 520 | |a Setting: Northeastern United States during the early phase of the COVID-19 pandemic. At the time of the survey, federal regulators had waived the longstanding requirement for in-office visits for MOUD prescription receipt and provided guidance on increasing third-party payer reimbursement rates for telehealth visits in order to mitigate barriers to care associated with COVID-19 safety guidelines | ||
| 520 | |a Participants: Individuals 18 years or older residing in Connecticut, Massachusetts, New Jersey, New York, or Rhode Island were eligible to complete the survey. The analytic sample was participants who reported using opioids not as prescribed by a physician in the past seven days | ||
| 520 | |a Measurements: Demographics, telemedicine usage, and healthcare coverage were assessed as explanatory variables. The primary outcome was whether participants reported ability to access MOUD in the past four weeks | ||
| 520 | |a Findings: In this sample of individuals who used illicit opioids in the past week (N = 191), one in two individuals who utilized telehealth or had healthcare coverage were able to access MOUD, whereas only one in five of their respective counterparts who did not have telehealth access or healthcare coverage were able to access these medications | ||
| 520 | |a Conclusions: Telemedicine and healthcare coverage were associated with greater MOUD access early in the COVID-19 pandemic, when barriers to care were high. Such findings speak to the importance of not only extending but also formalizing temporary policy changes instituted during the pandemic to allow MOUD prescribing via telemedicine | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 pandemic | |
| 650 | 4 | |a healthcare coverage | |
| 650 | 4 | |a medication assisted treatment | |
| 650 | 4 | |a medication for opioid use disorder | |
| 650 | 4 | |a telemedicine | |
| 650 | 4 | |a treatment access | |
| 700 | 1 | |a Clark, Samantha E |e verfasserin |4 aut | |
| 700 | 1 | |a Treloar Padovano, Hayley |e verfasserin |4 aut | |
| 700 | 1 | |a Sokolovsky, Alexander W |e verfasserin |4 aut | |
| 700 | 1 | |a Goodyear, Kimberly |e verfasserin |4 aut | |
| 700 | 1 | |a Ahluwalia, Jasjit S |e verfasserin |4 aut | |
| 700 | 1 | |a Monti, Peter M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Addictive behaviors reports |d 2015 |g 18(2023) vom: 18. Dez., Seite 100515 |w (DE-627)NLM250070553 |x 2352-8532 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g day:18 |g month:12 |g pages:100515 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.abrep.2023.100515 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |b 18 |c 12 |h 100515 | ||